With 3.7 million new cases each year, cancer is one of the leading causes of death and morbidity in the EU. Personalised cancer medicine (PCM) – an emerging approach that offers patients more precise and targeted diagnostics and treatment – has the potential to beat this disease. But currently, there is inequality in access to PCM between and within EU Member States.

As PCM is based on targeting driver mutations in tumours, its success depends on access to:

- next-generation sequencing-based molecular diagnostics,
- clinical decision support systems,
- trials to facilitate implementation of the PCM approach.

Combining the expertise of partners from 15 European countries, PCM4EU aims to improve the survival rates and quality of life of cancer patients in the EU, using PCM based on best practices. The project consortium has a good track record in implementing molecular diagnostics in academically-led cross-border PCM trials in north-western Europe. This expertise will be made available to support a wider use and access to PCM in Europe.

PCM4EU – Personalised cancer medicine for all EU citizens

Our project will contribute to the diagnosis and treatment area in the EU Cancer Plan, building on an existing collaboration with drug repurposing clinical trials, we aim to help other countries to implement this as well.

With 3.7 million new cases each year, cancer is one of the leading causes of death and morbidity in the EU. Personalised cancer medicine (PCM) – an emerging approach that offers patients more precise and targeted diagnostics and treatment – has the potential to beat this disease. But currently, there is inequality in access to PCM between and within EU Member States.

As PCM is based on targeting driver mutations in tumours, its success depends on access to:

- next-generation sequencing-based molecular diagnostics,
- clinical decision support systems,
- trials to facilitate implementation of the PCM approach.

Combining the expertise of partners from 15 European countries, PCM4EU aims to improve the survival rates and quality of life of cancer patients in the EU, using PCM based on best practices. The project consortium has a good track record in implementing molecular diagnostics in academically-led cross-border PCM trials in north-western Europe. This expertise will be made available to support a wider use and access to PCM in Europe.
PCM4EU will:

- evaluate current standards and provide best practice guidelines and recommendations on implementation and interpretation of state-of-the-art genomic diagnostics, supporting their implementation and interpretation;
- support development of harmonised European mechanisms for interpretation of molecular and clinical data so that information from cohorts of patients with rare mutations/tumour types in several countries can be analysed simultaneously to obtain faster answers;
- ensure cross-border access to PCM;
- facilitate incorporation of the project results into healthcare systems in a cost-effective way for future patients;
- provide education for all stakeholders, including physicians, pathologists, patients and decision makers.

For more info

**Contact details**
Prof. dr. Hans Gelderblom
Leiden University Medical Centre
Albinusdreef 2
Leiden
Netherlands
A.J.Gelderblom@lumc.nl
PCM4EU@LUMC.nl

**Project website**
https://www.pcm4eu.eu/

**Social media handles**
@PCM4EU

Europe's Beating Cancer Plan makes use of the whole range of Commission funding instruments with a total of €4 billion being earmarked for actions addressing cancer. €1.25 billion from the EU4Health programme is being used to support actions and initiatives outlined in the Cancer Plan.